Screener
Guardant Health GH Business Segments — Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Guardant Health in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The source filing: Guardant Health’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 5:16 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001576280-26-000026
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Revenue | $301,665 | $203,471 |
| Less: | ||
| Cost of revenue (1) | 101,560 | 72,185 |
| Research and development expense (1) | 76,589 | 74,897 |
| Sales and marketing expense (1) | 154,430 | 94,127 |
| General and administrative expense (1) | 37,037 | 30,559 |
| Other segment items (2) | 44,124 | 26,862 |
| Net loss | $(112,075) | $(95,159) |
Item 1. Unaudited Condensed Consolidated Financial Statements
FAQ
- What is Guardant Health's business segments — revenue?
- Guardant Health (GH) reported business segments — revenue of $301.67M in Q1 2026.
- How has Guardant Health's business segments — revenue changed year-over-year?
- Guardant Health's business segments — revenue increased by 48.3% year-over-year, from $203.47M to $301.67M.
- What is the long-term trend for Guardant Health's business segments — revenue?
- Over 3 years (2022 to 2025), Guardant Health's business segments — revenue has grown at a 29.8% compound annual growth rate (CAGR), from $449.54M to $982.02M.
- What does business segments — revenue mean?
- This represents the total gross income generated by the company's primary business segment through the sale of diagnostic tests and related services. It serves as the primary indicator of market adoption and commercial scale for the company's core product offerings.
Ask your AI about Guardant Health's business segments — revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude